Schrodinger, Inc. (NASDAQ:SDGR) Receives $20.50 Average Target Price from Analysts

Shares of Schrodinger, Inc. (NASDAQ:SDGR) have received a consensus rating of “Hold” from the seven research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $20.50.

A number of brokerages have issued reports on SDGR. UBS Group began coverage on Schrodinger in a research report on Friday, August 14th. They set a “neutral” rating and a $19.00 price objective on the stock. Wall Street Zen raised Schrodinger from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings raised shares of Schrodinger from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th.

Schrodinger Stock Performance

Shares of NASDAQ:SDGR opened at $29.23 on Friday. Schrodinger has a fifty-two week low of $10.94 and a fifty-two week high of $31.59. The firm has a fifty day moving average price of $19.34 and a 200 day moving average price of $15.57. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -39.50 and a beta of 1.69.

Schrodinger (NASDAQ:SDGR) last posted its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.49. The company had revenue of $58.89 million for the quarter, compared to the consensus estimate of $47.19 million. Schrodinger had a negative return on equity of 16.37% and a negative net margin of 20.98%.The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.65) earnings per share. As a group, research analysts predict that Schrodinger will post -1.5 earnings per share for the current year.

Insider Buying and Selling

In other Schrodinger news, insider Karen Akinsanya sold 31,599 shares of the stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $29.37, for a total transaction of $928,062.63. Following the completion of the sale, the insider directly owned 69,956 shares of the company’s stock, valued at approximately $2,054,607.72. This represents a 31.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Rubric Capital Management LP increased its holdings in shares of Schrodinger by 43.8% during the first quarter. Rubric Capital Management LP now owns 6,000,000 shares of the company’s stock valued at $68,160,000 after acquiring an additional 1,828,502 shares in the last quarter. Quantinno Capital Management LP acquired a new stake in Schrodinger in the 1st quarter worth approximately $1,978,000. Tejara Capital Ltd purchased a new stake in Schrodinger during the 2nd quarter worth approximately $4,553,000. BlackRock Inc. purchased a new stake in Schrodinger during the 2nd quarter worth approximately $170,978,000. Finally, Beacon Pointe Advisors LLC acquired a new position in Schrodinger during the 2nd quarter valued at approximately $839,000. 79.05% of the stock is owned by institutional investors and hedge funds.

About Schrodinger

Schrödinger, Inc develops computational software designed to accelerate drug discovery and materials science research. Its platform uses physics-based modeling, machine learning and related computational methods to help scientists analyze molecular structures, predict interactions and identify potential compounds for further development.

The company’s software products support a range of research activities, including molecular modeling, virtual screening, structure-based drug design, free-energy calculations and collaborative data management.